Discovery of a B-Cell Lymphoma 6 Protein–Protein Interaction Inhibitor by a Biophysics-Driven Fragment-Based Approach-Reference-Cited by-同舟云学术

Discovery of a B-Cell Lymphoma 6 Protein–Protein Interaction Inhibitor by a Biophysics-Driven Fragment-Based Approach

Published:2017-05-11 Issue:10 Volume:60 Page:4358-4368
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Kamada Yusuke¹^ORCID,Sakai Nozomu¹,Sogabe Satoshi¹,Ida Koh¹,Oki Hideyuki¹,Sakamoto Kotaro¹,Lane Weston²,Snell Gyorgy²,Iida Motoo¹,Imaeda Yasuhiro¹,Sakamoto Junichi¹,Matsui Junji¹

Affiliation:

1. Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan

2. Takeda California Inc., 10410 Science Center Dr., San Diego, California 92121, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.7b00313

Reference46 articles.

1. Control of Inflammation, Cytokine Expression, and Germinal Center Formation by BCL-6

2. Signals that influence T follicular helper cell differentiation and function

3. Bcl6 Mediates the Development of T Follicular Helper Cells

4. RNA interference targeting Bcl-6 ameliorates experimental autoimmune myasthenia gravis in mice

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging and Re-emerging Warheads for Targeted Covalent Inhibitors: An Update;Journal of Medicinal Chemistry;2024-05-07

2. Discovery of an In Vivo Chemical Probe for BCL6 Inhibition by Optimization of Tricyclic Quinolinones;Journal of Medicinal Chemistry;2023-04-07

3. Discovery of OICR12694: A Novel, Potent, Selective, and Orally Bioavailable BCL6 BTB Inhibitor;ACS Medicinal Chemistry Letters;2023-01-12

4. Reactive fragments targeting carboxylate residues employing direct to biology, high-throughput chemistry;RSC Medicinal Chemistry;2023

5. Protein–Protein Interactions in Cancer;Protein-Protein Interactions;2023